Priovant Therapeutics announces strong Phase 2 NEPTUNE study results for brepocitinib in non-infectious uveitis, displaying the best efficacy data to date.

Priovant Therapeutics announced positive Phase 2 NEPTUNE study results for brepocitinib in non-infectious uveitis (NIU), demonstrating the strongest efficacy data in NIU to date. In the study, 29% of subjects receiving brepocitinib 45 mg and 44% of subjects receiving brepocitinib 15 mg met the pre-specified primary efficacy endpoint of treatment failure at week 24. All secondary efficacy endpoints were also positive and dose responsive. The results position brepocitinib as a potentially transformative once-daily oral therapy for this debilitating disease.

April 02, 2024
8 Articles

Further Reading